Delving into the Latest Updates on Selectus Pharmaceuticals, Inc. with Synapse

Overview

A review with 26 referencesEsprolol is a new, potent, beta adrenergic receptor antagonist that is differentiated from available drugs of this class by its rapid onset, short time to peak effect, and relatively short duration of action after sublingual and oral administration.The drug has potential for short-term use in patients with exertional angina and in patients with other diseases in which rapid-onset beta blocking action would be beneficial.The unique properties of esprolol are determined by the presence in its chem. structure of an ester group, which undergoes rapid metabolism by blood and tissue esterases to form an active metabolite, amoxolol.Preclin. testing and clin. trials in healthy volunteers have demonstrated the tolerability, pharmacokinetics, and beta adrenergic blocking properties of both esprolol and amoxolol.An ongoing trial to evaluate its usefulness in improving exercise performance in patients with exertional angina pectoris is nearing completion.

Heart disease (Hagerstown, Md.)

Esprolol hydrochloride: a new beta adrenergic antagonist with a rapid onset of effect.

Author: Patil G ; Matier Wl

Esprolol is a new, potent, beta adrenergic receptor antagonist that is differentiated from available drugs of this class by its rapid onset, short time to peak effect, and relatively short duration of action after sublingual and oral administration. The drug has potential for short-term use in patients with exertional angina and in patients with other diseases in which rapid-onset beta blocking action would be beneficial. The unique properties of esprolol are determined by the presence in its chemical structure of an ester group, which undergoes rapid metabolism by blood and tissue esterases to form an active metabolite, amoxolol. Preclinical testing and clinical trials in healthy volunteers have demonstrated the tolerability, pharmacokinetics, and beta adrenergic blocking properties of both esprolol and amoxolol. An ongoing trial to evaluate its usefulness in improving exercise performance in patients with exertional angina pectoris is nearing completion.

Heart disease (Hagerstown, Md.)

Esprolol hydrochloride: a new beta adrenergic antagonist with a rapid onset of effect.

Article

Author: Patil, G ; Matier, W L

Esprolol is a new, potent, beta adrenergic receptor antagonist that is differentiated from available drugs of this class by its rapid onset, short time to peak effect, and relatively short duration of action after sublingual and oral administration. The drug has potential for short-term use in patients with exertional angina and in patients with other diseases in which rapid-onset beta blocking action would be beneficial. The unique properties of esprolol are determined by the presence in its chemical structure of an ester group, which undergoes rapid metabolism by blood and tissue esterases to form an active metabolite, amoxolol. Preclinical testing and clinical trials in healthy volunteers have demonstrated the tolerability, pharmacokinetics, and beta adrenergic blocking properties of both esprolol and amoxolol. An ongoing trial to evaluate its usefulness in improving exercise performance in patients with exertional angina pectoris is nearing completion.

100 Deals associated with Selectus Pharmaceuticals, Inc.

Login to view more data

100 Translational Medicine associated with Selectus Pharmaceuticals, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 21 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Beta-blocker(Selectus) ( β-adrenoceptors )	Glaucoma More	Discontinued
Esprolol Hydrochloride ( β-adrenoceptors )	Migraine Disorders More	Discontinued
SL-1111 ( β-adrenoceptors )	Glaucoma More	Discontinued